Adam B Murphy1, Samuel Carbunaru2, Oluwarotimi S Nettey2, Chase Gornbein2, Michael A Dixon2, Virgilia Macias3, Roohollah Sharifi4, Rick A Kittles5, Ximing Yang6, Andre Kajdacsy-Balla3, Peter Gann3. 1. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address: a-murphy2@northwestern.edu. 2. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. 3. Department of Pathology, University of Illinois at Chicago School of Medicine, Chicago, IL. 4. Section of Urology, Jesse Brown VA Medical Center, Chicago, IL; Department of Urology, University of Illinois at Chicago School of Medicine, Chicago, IL. 5. Division of Health Equities, Department of Population Sciences, City of Hope Cancer Center, Duarte, CA(.). 6. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Abstract
OBJECTIVE: To validate the 17-gene Oncotype DX Genomic Prostate Score (GPS) as a predictor of adverse pathology (AP) in African American (AA) men and to assess the distribution of GPS in AA and European American (EA) men with localized prostate cancer. METHODS: The study populations were derived from 2 multi-institutional observational studies. Between February 2009 and September 2014, AA and EA men who elected immediate radical prostatectomy after a ≥10-core transrectal ultrasound biopsy were included in the study. Logistic regressions, area under the receiver operating characteristics curves (AUC), calibration curves, and predictive values were used to compare the accuracy of GPS. AP was defined as primary Gleason grade 4, presence of any Gleason pattern 5, and/or non-organ-confined disease (≥pT3aN0M0) at radical prostatectomy. RESULTS: Overall, 96 AA and 76 EA men were selected and 46 (26.7%) had AP. GPS result was a significant predictor of AP (odds ratio per 20 GPS units [OR/20 units] in AA: 4.58; 95% confidence interval (CI) 1.8-11.5, P = .001; and EA: 4.88; 95% CI 1.8-13.5, P = .002). On multivariate analysis, there was no significant interaction between GPS and race (P >.10). GPS remained significant in models adjusted for either National Comprehensive Cancer Network (NCCN) risk group or Cancer of the Prostate Risk Assessment (CAPRA) score. In race-stratified models, area under the receiver operating characteristics curves for GPS/20 units was 0.69 for AAs vs 0.74 for EAs (P = .79). The GPS distributions were not statistically different by race (all P >.05). CONCLUSION: In this clinical validation study, the Oncotype DX GPS is an independent predictor of AP at prostatectomy in AA and EA men with similar predictive accuracy and distributions. Published by Elsevier Inc.
OBJECTIVE: To validate the 17-gene Oncotype DX Genomic Prostate Score (GPS) as a predictor of adverse pathology (AP) in African American (AA) men and to assess the distribution of GPS in AA and European American (EA) men with localized prostate cancer. METHODS: The study populations were derived from 2 multi-institutional observational studies. Between February 2009 and September 2014, AA and EA men who elected immediate radical prostatectomy after a ≥10-core transrectal ultrasound biopsy were included in the study. Logistic regressions, area under the receiver operating characteristics curves (AUC), calibration curves, and predictive values were used to compare the accuracy of GPS. AP was defined as primary Gleason grade 4, presence of any Gleason pattern 5, and/or non-organ-confined disease (≥pT3aN0M0) at radical prostatectomy. RESULTS: Overall, 96 AA and 76 EA men were selected and 46 (26.7%) had AP. GPS result was a significant predictor of AP (odds ratio per 20 GPS units [OR/20 units] in AA: 4.58; 95% confidence interval (CI) 1.8-11.5, P = .001; and EA: 4.88; 95% CI 1.8-13.5, P = .002). On multivariate analysis, there was no significant interaction between GPS and race (P >.10). GPS remained significant in models adjusted for either National Comprehensive Cancer Network (NCCN) risk group or Cancer of the Prostate Risk Assessment (CAPRA) score. In race-stratified models, area under the receiver operating characteristics curves for GPS/20 units was 0.69 for AAs vs 0.74 for EAs (P = .79). The GPS distributions were not statistically different by race (all P >.05). CONCLUSION: In this clinical validation study, the Oncotype DX GPS is an independent predictor of AP at prostatectomy in AA and EA men with similar predictive accuracy and distributions. Published by Elsevier Inc.
Authors: Ricardo F Sanchez-Ortiz; Patricia Troncoso; Richard J Babaian; Josep Lloreta; Dennis A Johnston; Curtis A Pettaway Journal: Cancer Date: 2006-07-01 Impact factor: 6.860
Authors: Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Farzana A Faisal; Debasish Sundi; Jeffrey J Tosoian; Voleak Choeurng; Mohammed Alshalalfa; Ashley E Ross; Eric Klein; Robert Den; Adam Dicker; Nicholas Erho; Elai Davicioni; Tamara L Lotan; Edward M Schaeffer Journal: Eur Urol Date: 2015-10-09 Impact factor: 20.096
Authors: Philip Rosen; David Pfister; Denise Young; Gyorgy Petrovics; Yongmei Chen; Jennifer Cullen; Diana Böhm; Sven Perner; Albert Dobi; David G McLeod; Isabell A Sesterhenn; Shiv Srivastava Journal: Urology Date: 2012-08-28 Impact factor: 2.649
Authors: Jonathan B Bloom; Amir H Lebastchi; Samuel A Gold; Graham R Hale; Thomas Sanford; Sherif Mehralivand; Michael Ahdoot; Kareem N Rayn; Marcin Czarniecki; Clayton Smith; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter L Choyke; Howard L Parnes; Baris Turkbey; Peter A Pinto Journal: BJU Int Date: 2019-06-26 Impact factor: 5.969
Authors: Yuanshuo Alice Wang; John Sfakianos; Ashutosh K Tewari; Carlos Cordon-Cardo; Natasha Kyprianou Journal: Oncogene Date: 2020-10-12 Impact factor: 9.867